Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $14.75 Average Target Price from Brokerages

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have been assigned an average rating of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the last year is $14.75.

Several equities analysts have weighed in on the company. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Tenaya Therapeutics in a report on Friday, October 18th. Leerink Partners reissued an "outperform" rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Piper Sandler reaffirmed an "overweight" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group reissued a "buy" rating and issued a $16.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Chardan Capital decreased their target price on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, November 7th.

Tenaya Therapeutics Stock Up 10.2 %

TNYA stock traded up $0.22 during trading on Friday, reaching $2.38. The company's stock had a trading volume of 3,015,121 shares, compared to its average volume of 5,408,264. The company's fifty day moving average is $2.02 and its 200-day moving average is $2.87. The company has a market capitalization of $188.55 million, a P/E ratio of -1.65 and a beta of 2.34. Tenaya Therapeutics has a 1 year low of $1.61 and a 1 year high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Analysts anticipate that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Tenaya Therapeutics

Several institutional investors have recently made changes to their positions in TNYA. abrdn plc purchased a new position in Tenaya Therapeutics during the 3rd quarter valued at $1,063,000. Vanguard Group Inc. boosted its stake in shares of Tenaya Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company's stock valued at $14,973,000 after purchasing an additional 403,472 shares during the period. American Century Companies Inc. grew its holdings in shares of Tenaya Therapeutics by 27.7% in the second quarter. American Century Companies Inc. now owns 102,114 shares of the company's stock worth $317,000 after purchasing an additional 22,146 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Tenaya Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company's stock worth $316,000 after buying an additional 30,446 shares during the period. Finally, Algert Global LLC bought a new stake in Tenaya Therapeutics during the 2nd quarter valued at about $74,000. Institutional investors own 90.54% of the company's stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.